175 related articles for article (PubMed ID: 17823852)
1. Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma.
Prazeres HJ; Rodrigues F; Soares P; Naidenov P; Figueiredo P; Campos B; Lacerda M; Martins TC
Fam Cancer; 2008; 7(2):141-9. PubMed ID: 17823852
[TBL] [Abstract][Full Text] [Related]
2. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
3. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.
McKay JD; Thompson D; Lesueur F; Stankov K; Pastore A; Watfah C; Strolz S; Riccabona G; Moncayo R; Romeo G; Goldgar DE
J Med Genet; 2004 Jun; 41(6):407-12. PubMed ID: 15173224
[TBL] [Abstract][Full Text] [Related]
4. Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors.
Stankov K; Pastore A; Toschi L; McKay J; Lesueur F; Kraimps JL; Bonneau D; Gibelin H; Levillain P; Volante M; Papotti M; Romeo G
Int J Cancer; 2004 Sep; 111(3):463-7. PubMed ID: 15221978
[TBL] [Abstract][Full Text] [Related]
5. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2.
Canzian F; Amati P; Harach HR; Kraimps JL; Lesueur F; Barbier J; Levillain P; Romeo G; Bonneau D
Am J Hum Genet; 1998 Dec; 63(6):1743-8. PubMed ID: 9837827
[TBL] [Abstract][Full Text] [Related]
6. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
7. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis.
Cavaco BM; Batista PF; Sobrinho LG; Leite V
J Clin Endocrinol Metab; 2008 Nov; 93(11):4426-30. PubMed ID: 18765515
[TBL] [Abstract][Full Text] [Related]
8. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity.
Yang TL; Su YR; Huang CS; Yu JC; Lo YL; Wu PE; Shen CY
Genes Chromosomes Cancer; 2004 Nov; 41(3):250-6. PubMed ID: 15334548
[TBL] [Abstract][Full Text] [Related]
9. 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer.
Trojan J; Brieger A; Raedle J; Esteller M; Zeuzem S
Gut; 2000 Aug; 47(2):272-6. PubMed ID: 10896921
[TBL] [Abstract][Full Text] [Related]
10. Mapping of a gene predisposing to familial thyroid tumors with cell oxyphilia to chromosome 19 and exclusion of JUN B as a candidate gene.
Kraimps JL; Canzian F; Jost C; Menet E; Amati P; Levillian P; Harach R; Lesueur F; Barbier J; Romeo G; Bonneau D
Surgery; 1999 Dec; 126(6):1188-94. PubMed ID: 10598206
[TBL] [Abstract][Full Text] [Related]
11. The familial counterparts of follicular cell--derived thyroid tumors.
Prazeres H; Torres J; Soares P; Sobrinho-Simões M
Int J Surg Pathol; 2010 Aug; 18(4):233-42. PubMed ID: 20444727
[TBL] [Abstract][Full Text] [Related]
12. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas.
Khosla S; Patel VM; Hay ID; Schaid DJ; Grant CS; van Heerden JA; Thibodeau SN
J Clin Invest; 1991 May; 87(5):1691-9. PubMed ID: 2022740
[TBL] [Abstract][Full Text] [Related]
14. Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors?
Tsuji T; Catasus L; Prat J
Hum Pathol; 2005 Jul; 36(7):792-6. PubMed ID: 16084949
[TBL] [Abstract][Full Text] [Related]
15. LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13.
Fiedler U; Ehlers W; Meye A; Füssel S; Faller G; Schmidt U; Wirth MP
Anticancer Res; 2001; 21(4A):2341-50. PubMed ID: 11724291
[TBL] [Abstract][Full Text] [Related]
16. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2.
Mulligan LM; Gardner E; Smith BA; Mathew CG; Ponder BA
Genes Chromosomes Cancer; 1993 Mar; 6(3):166-77. PubMed ID: 7682102
[TBL] [Abstract][Full Text] [Related]
17. Familial nonmedullary thyroid cancer: a review of the genetics.
Khan A; Smellie J; Nutting C; Harrington K; Newbold K
Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 1 (MEN1): LOH studies in a affected family and in sporadic cases.
Valdes N; Alvarez V; Diaz-Cadorniga F; Aller J; Villazon F; Garcia I; Herrero A; Coto E
Anticancer Res; 1998; 18(4A):2685-9. PubMed ID: 9703929
[TBL] [Abstract][Full Text] [Related]
19. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
Xu XF; Tang PZ; Cheng SJ
Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.
Beghelli S; Pelosi G; Zamboni G; Falconi M; Iacono C; Bordi C; Scarpa A
J Pathol; 1998 Sep; 186(1):41-50. PubMed ID: 9875139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
